

1FW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))


Docket No.
19215

In Re Application Of: **Gail Petuna Risbridger, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/551,352	October 4, 2006	Catherine Joyce	23389	1642	6430

Title:

DIAGNOSIS OF ADVANCED CANCER



Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
19215

In Re Application of: Gail Petuna Risbridger, et al.

SEP 13 2007

Application No. 10/551,352	Filing Date October 4, 2006	Examiner Catherine Joyce	Customer No. 23389	Group Art Unit 1642	Confirmation No. 6430
-------------------------------	--------------------------------	-----------------------------	-----------------------	------------------------	--------------------------

Title:

DIAGNOSIS OF ADVANCED CANCER

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

September 10, 2007
(Date)

Xiaochun Zhu
Signature of Person Mailing Correspondence

Xiaochun Zhu
Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Dated: September 10, 2007


Xiaochun Zhu
Registration No. 56,311
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

CC:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
19215

In Re Application Of: **Gail Petuna Risbridger, et al.**



Application No.

Filing Date

Examiner

Customer No.

Group Art Unit

Confirmation No.

10/551,352

October 4, 2006

Catherine Joyce

23389

1642

6430

Title:

DIAGNOSIS OF ADVANCED CANCER

Address to:

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);


OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(h) or 1.97(c))

Docket No.
19215

In Re Application of: Gail Petuna Risbridger, et al.



Application No. 10/551,352	Filing Date October 4, 2006	Examiner Catherine Joyce	Customer No. 23389	Group Art Unit 1642	Confirmation No. 6430
-------------------------------	--------------------------------	-----------------------------	-----------------------	------------------------	--------------------------

Title:

DIAGNOSIS OF ADVANCED CANCER

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)


Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

September 10, 2007
(Date)


Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: September 10, 2007

Xiaochun Zhu
Registration No. 56,311
Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
516-742-4343

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gail Petuna Risbridger, et al.

Examiner: Catherine Joyce

Serial No.: 10/551,352

Art Unit: 1642

Filed: October 4, 2006

Docket: 19215

For: DIAGNOSIS OF ADVANCED CANCER

Dated: September 10, 2007

Confirmation No.: 6430

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Australian Patent Application No. 2001-10078 B2, published April 30, 2001 (abstract), corresponding to PCT International Publication No. WO 01/29079 A1, published April 26, 2001;
2. Derwent Accession No. 2001-308476 (abstract only);
3. Risbridger G.P., "Recent Progress in Our Understanding of Inhibin in the Prostate Gland", *Journal of Endocrinology* 157(1):1-4 (1998);

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 10, 2007


Xiaochun Zhu

4. Mellor S.L. et al., "Loss of the Expression and Localization of Inhibin α -Subunit in High Grade Prostate Cancer", *Journal of Clinical Endocrinology and Metabolism* 83(3):969-975 (1998);
5. United States Patent Application Publication No. 2003/235820 A1, published December 25, 2003 to Mack et al.;
6. Risbridger G.P. et al., "Elevated Expression of Inhibin α in Prostate Cancer", *The Journal of Urology* 171(1):192-196 (2004);
7. PCT International Publication No. WO 95/032431 A1, published November 30, 1995;
8. PCT International Publication No. WO 87/05702 A1, published September 24, 1987;
9. PCT International Publication No. WO 01/29079 A1, published April 26, 2001;
10. PCT International Publication No. WO 98/47526 A1, published October 29, 1998;
11. Sheth N.A. et al., "Circulating Levels of Inhibin in Cancer", *Neoplasma* 31(3):315-321 (1984);
12. Robertson D.M. et al., "Development of an Inhibin α Subunit ELISA with Broad Specificity", *Molecular and Cellular Endocrinology* 180:79-86 (2001);
13. Betteridge A. et al., "A Two-Site Enzyme-Linked Immunosorbent Assay for Inhibin", *Biology of Reproduction* 45:748-754 (1991);
14. Frias, Jr. A.E. et al., "Preoperative Serum Level of Inhibin A is an Independent Prognostic Factor for the Survival of Postmenopausal Women with Epithelial Ovarian Carcinoma", *Cancer* 85(2):465-471 (1999);
15. Petraglia F. et al., "Inhibin B is the Major Form of Inhibin/Activin Family Secreted by Granulosa Cell Tumors", *Journal of Clinical Endocrinology and Metabolism* 83(3):1029-1032 (1998);
16. Robertson D.M. et al., "Inhibins/Activins as Diagnostic Markers for Ovarian Cancer", *Molecular and Cellular Endocrinology* 191:97-103 (2002); and
17. Dowling C.R. et al., "The Role of Inhibins and Activins in Prostate Cancer Pathogenesis", *Endocrine-Related Cancer* 7:243-256 (2000).

References 1-6 were cited in a Supplementary Partial Search Report dated November 7, 2006 received from the European Patent Office. References 4, 7-17 were cited in an International Search Report dated June 8, 2004 received from the Australian Patent Office. A copy of the International Search Report was previously submitted by Applicants on September 28, 2005. Applicants are submitting copies of Reference Nos. 1-4 and 6-17, as required by 37 C.F.R. §1.98 (a)(2)(i) and (ii), together with a copy of the Supplementary Partial European Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,


A handwritten signature in black ink, appearing to read 'Xiaochun Zhu', written in a cursive style.

Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343
XZ:dg

Form PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**LIST OF PRIOR ART
CITED BY APPLICANT**

(Use several sheets if necessary)



Atty. Docket No.

19215

Serial No.

10/551,352

Applicants

Gail Petuna Risbridger, et al.

Filing Date

October 4, 2006

Group Art Unit

1642

U.S. PATENT PUBLICATION DOCUMENTS

		2003/235820 A1	12/25/03	Mack et al.			
--	--	----------------	----------	-------------	--	--	--

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 95/032431 A1	11/30/95	PCT			✓	
		WO 87/05702 A1	9/24/87	PCT			✓	
		WO 01/29079 A1	4/26/01	PCT			✓	
		WO 98/47526 A1	10/29/98	PCT			✓	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		Australian Patent Application No. 2001-10078 B2, published April 30, 2001 (abstract), corresponding to PCT International Publication No. WO 01/29079 A1, published April 26, 2001
		Derwent Accession No. 2001-308476 (abstract only)
		Risbridger G.P., "Recent Progress in Our Understanding of Inhibin in the Prostate Gland", <i>Journal of Endocrinology</i> 157(1):1-4 (1998)
		Mellor S.L. et al., "Loss of the Expression and Localization of Inhibin α -Subunit in High Grade Prostate Cancer", <i>Journal of Clinical Endocrinology and Metabolism</i> 83(3):969-975 (1998)
		Risbridger G.P. et al., "Elevated Expression of Inhibin α in Prostate Cancer", <i>The Journal of Urology</i> 171(1):192-196 (2004)
		Sheth N.A. et al., "Circulating Levels of Inhibin in Cancer", <i>Neoplasma</i> 31(3):315-321 (1984)
		Robertson D.M. et al., "Development of an Inhibin α Subunit ELISA with Broad Specificity", <i>Molecular and Cellular Endocrinology</i> 180:79-86 (2001)
		Betteridge A. et al., "A Two-Site Enzyme-Linked Immunosorbent Assay for Inhibin", <i>Biology of Reproduction</i> 45:748-754 (1991)
		Frias, Jr. A.E. et al., "Preoperative Serum Level of Inhibin A is an Independent Prognostic Factor for the Survival of Postmenopausal Women with Epithelial Ovarian Carcinoma", <i>Cancer</i> 85(2):465-471 (1999)
		Petraglia F. et al., "Inhibin B is the Major Form of Inhibin/Activin Family Secreted by Granulosa Cell Tumors", <i>Journal of Clinical Endocrinology and Metabolism</i> 83(3):1029-1032 (1998)
		Robertson D.M. et al., "Inhibins/Activins as Diagnostic Markers for Ovarian Cancer", <i>Molecular and Cellular Endocrinology</i> 191:97-103 (2002)
		Dowling C.R. et al., "The Role of Inhibins and Activins in Prostate Cancer Pathogenesis", <i>Endocrine-Related Cancer</i> 7:243-256 (2000)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.